EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers

Vera Tiedje, Jillian Greenberg, Tianyue Qin, Soo-Yeon Im, Gnana P Krishnamoorthy, Laura Boucai, Bin Xu, Jena D French, Eric J Sherman, Alan L Ho, Elisa de Stanchina, Nicholas D Socci und 5 weitere

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci191781 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Vera Tiedje und 16 weiteren Autor:innen. Beteiligte Einrichtung: Human Oncology and Pathogenesis Program. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Thyroid Carcinoma, Anaplastic, Protein Kinase Inhibitors, Histocompatibility Antigens Class II. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer cells present neoantigens dominantly through MHC class I (MHCI) to drive tumor rejection through cytotoxic CD8 + T cells. There is growing recognition that a subset of tumors express MHC class II (MHCII), causing recognition of antigens by TCRs of CD4 + T cells that contribute to the antitumor response. We found that mouse Braf V600E -driven anaplastic thyroid cancers (ATCs) responded markedly to the RAF plus MEK inhibitors dabrafenib and trametinib (dab/tram) and that this was associated with upregulation of MhcII in cancer cells and increased CD4 + T cell infiltration. A subset of recurrent tumors lost MhcII expression due to silencing of Ciita , the master transcriptional regulator of MhcII , despite preserved IFN-γ signal transduction, which could be rescued by EZH2 inhibition. Orthotopically implanted Ciita –/– and H2-Ab1 –/– ATC cells into immune-competent mice became unresponsive to the MAPK inhibitors. Moreover, depletion of CD4 + , but not CD8 + , T cells also abrogated the response to dab/tram. These findings implicate MHCII-driven CD4 + T cell activation as a key determinant of the response of Braf -mutant ATCs to MAPK inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafThyroid Carcinoma, AnaplasticProtein Kinase InhibitorsHistocompatibility Antigens Class IIThyroid NeoplasmsMutationDrug Resistance, NeoplasmAnimalsMicePyridonesOximesCD4-Positive T-LymphocytesHumansPyrimidinonesCell Line, TumorCD8-Positive T-LymphocytesImidazolesTrans-ActivatorsNuclear ProteinsMice, KnockoutMAP Kinase Signaling System

Stichwörter der Autor:innen

AntigenCancerEndocrinologyImmunologyThyroid disease

Substanzen

Proto-Oncogene Proteins B-rafProtein Kinase InhibitorsPyridonesBraf protein, mouseHistocompatibility Antigens Class IItrametinibOximesdabrafenibPyrimidinonesMHC class II transactivator protein

Autor:innen und Institutionen

  • Human Oncology and Pathogenesis Program.
  • Department of Medicine, and.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, and.
  • University of Colorado Cancer Center, University of Colorado Denver, Aurora, Colorado, USA.
  • Antitumor Assessment Core Facility and.

Förderung

  • NCI NIH HHS
  • NIH

Zitieren

APA

Tiedje, V., Greenberg, J., Qin, T., Im, S. Y., Krishnamoorthy, G. P., Boucai, L., Xu, B., French, J. D., Sherman, E. J., Ho, A. L., de Stanchina, E., Socci, N. D., Jin, J., Ghossein, R. A., Knauf, J. A., Koche, R. P., & Fagin, J. A. (2025). Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers. Journal of Clinical Investigation. https://doi.org/10.1172/jci191781

Vancouver

Tiedje V, Greenberg J, Qin T, Im SY, Krishnamoorthy GP, Boucai L, et al. Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers. Journal of Clinical Investigation. 2025. doi:10.1172/jci191781

BibTeX
@article{Tiedje2025,
  author = {Tiedje, Vera and Greenberg, Jillian and Qin, Tianyue and Im, Soo-Yeon and Krishnamoorthy, Gnana P and Boucai, Laura and Xu, Bin and French, Jena D and Sherman, Eric J and Ho, Alan L and de Stanchina, Elisa and Socci, Nicholas D and Jin, Jian and Ghossein, Ronald A and Knauf, Jeffrey A and Koche, Richard P and Fagin, James A},
  title = {Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci191781}
}
Kostenlos starten →